MUMBAI, India, Feb. 13 -- Intellectual Property India has published a patent application (202521133448 A) filed by Dr. Kakad Subhash Lahanbhau; Dr. Aher Haribhau R.; Dr. Dighe Pradeep Machindra; Dr. Pawar Ramnath Appasaheb; Dr. Kailas L. Vairal; Mr. Pehere Babasaheb Mohan; Mr. Tambe Harshad Sanjay; Mr. Wagh Mahesh Subhash; Dr. Vikhe Amol Madhukar; and Ms. Sonali Chandrabhan Magar, Pune, Maharashtra, on Dec. 30, 2025, for 'green fabrication of silver nanoparticles using ethanolic leaf extract of mentha arvensis l. and evaluation of their pharmacological efficacy.'
Inventor(s) include Dr. Kakad Subhash Lahanbhau; Dr. Aher Haribhau R.; Dr. Dighe Pradeep Machindra; Dr. Pawar Ramnath Appasaheb; Dr. Kailas L. Vairal; Mr. Pehere Babasaheb Mohan; Mr. Tambe Harshad Sanjay; Mr. Wagh Mahesh Subhash; Dr. Vikhe Amol Madhukar; and Ms. Sonali Chandrabhan Magar.
The application for the patent was published on Feb. 13, under issue no. 07/2026.
According to the abstract released by the Intellectual Property India: "The invention discloses an eco-friendly process for synthesizing silver nanoparticles (AgNPs) using ethanolic leaf extract of Mentha arvensis L. as a dual-function reducing and stabilizing agent, together with compositions, characterization, and biomedical applications thereof. Authenticated plant material is extracted under controlled conditions to obtain a standardized phytochemical profile. Aqueous silver precursor solutions are reduced by the extract at defined ratios, pH, and temperature to generate stable colloidal AgNPs. Nanoparticle formation and quality are confirmed by UV-Visible spectroscopy through surface plasmon resonance features, FTIR for functional group interactions, XRD for crystalline phase identification, SEM for morphology and size, and EDX for elemental composition. The invention further provides acceptance criteria linking analytics to performance and demonstrates biological utility via in vitro antimicrobial testing against selected microorganisms, thrombolytic assays employing streptokinase as a positive control and water as a negative control, and MTT cytotoxicity evaluations indicating preliminary anticancer potential. By eliminating hazardous reagents and leveraging plant-derived capping layers, the method enhances biocompatibility, reduces environmental impact, and supports cost-effective scale-up. The claimed platform delivers reproducible, application-ready AgNPs suitable for research and potential translational development in antimicrobial, thrombolytic, and anticancer contexts, with defined processing and formulation options for suspension, hydrogel, film, and coating formats."
Disclaimer: Curated by HT Syndication.
